• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

People on Ozempic may have fewer heart attacks, strokes, addictions—but more nausea, vomiting, stomach pain

January 26, 2025
in Medical Research
Reading Time: 5 mins read
A A
0
Ozempic
5
SHARES
11
VIEWS
Share on FacebookShare on Twitter


Ozempic
Credit: Pixabay/CC0 Public Domain

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity.

The dramatic effects of these drugs, known as GLP-1s, on weight loss have sparked huge public interest in this new treatment option.

However, the risks and benefits are still being actively studied.

In a new study in Nature Medicine, researchers from the United States reviewed health data from about 2.4 million people who have type 2 diabetes, including around 216,000 people who used a GLP-1 drug, between 2017 and 2023.

The researchers compared a range of health outcomes when GLP-1s were added to a person’s treatment plan, versus managing their diabetes in other ways, often using glucose-lowering medications.

Overall, they found people who used GLP-1s were less likely to experience 42 health conditions or adverse health events—but more likely to face 19 others.

What conditions were less common?

  • Cardiometabolic conditions. GLP-1 use was associated with fewer serious cardiovascular and coagulation disorders. This includes deep vein thrombosis, pulmonary embolism, stroke, cardiac arrest, heart failure and myocardial infarction.
  • Neurological and psychiatric conditions. GLP-1 use was associated with fewer reported substance use disorders or addictions, psychotic disorders and seizures.
  • Infectious conditions. GLP-1 use was associated with fewer bacterial infections and pneumonia.

What conditions were more common?

  • Gastrointestinal conditions. Consistent with prior studies, GLP-1 use was associated with gastrointestinal conditions such as nausea, vomiting, gastritis, diverticulitis and abdominal pain.
  • Other adverse effects. Increased risks were seen for conditions such as low blood pressure, syncope (fainting) and arthritis.

How robust is this study?

The study used a large and reputable dataset from the US Department of Veterans Affairs. It’s an observational study, meaning the researchers tracked health outcomes over time without changing anyone’s treatment plan.

A strength of the study is it captures data from more than 2.4 million people across more than six years. This is much longer than what is typically feasible in an intervention study.

Observational studies like this are also thought to be more reflective of the “real world,” because participants aren’t asked to follow instructions to change their behavior in unnatural or forced ways, as they are in intervention studies.

However, this study cannot say for sure that GLP-1 use was the cause of the change in risk of different health outcomes. Such conclusions can only be confidently made from tightly controlled intervention studies, where researchers actively change or control the treatment or behavior.

The authors note the data used in this study comes from predominantly older, white men, so the findings may not apply to other groups.

Also, the large number of participants means that even very small effects can be detected, but they might not actually make a real difference in overall population health.

Other possible reasons for these links

Beyond the effect of GLP-1 in the body, other factors may explain some of the findings in this study. For example, it’s possible that:

  • People who used GLP-1 could be more informed about treatment options and more motivated to manage their own health
  • People who used GLP-1 may have received it because their health-care team were motivated to offer the latest treatment options, which could lead to better care in other areas that impact the risk of various health outcomes
  • People who used GLP-1 may have been able to do so because they lived in metropolitan centers and could afford the medication, as well as other health-promoting services and products, such as gyms, mental health care, or healthy food delivery services.

Did the authors have any conflicts of interest?

Two of the study’s authors declared they were “uncompensated consultants” for Pfizer, a global pharmaceutical company known for developing a wide range of medicines and vaccines. While Pfizer does not currently make readily available GLP-1s such as Ozempic or Wegovy, they are attempting to develop their own GLP-1s, so may benefit from greater demand for these drugs.

This research was funded by the US Department of Veterans Affairs, a government agency that provides a wide range of services to military veterans.

No other competing interests were reported.

Diabetes vs. weight-loss treatments

Overall, this study shows people with type 2 diabetes using GLP-1 medication generally have more positive health outcomes than negative health outcomes.

However, the study didn’t include people without type 2 diabetes. More research is needed to understand the effects of these medications in people without diabetes who are using them for other reasons, including weight loss.

While the findings highlight the therapeutic benefits of GLP-1 medications, they also raise important questions about how to manage the potential risks for those who choose to use this medication.

The findings of this study can help many people, including:

  • policymakers looking at ways to make GLP-1 medications more widely available for people with various health conditions
  • health professionals who have regular discussions with patients considering GLP-1 use
  • individuals considering whether a GLP-1 medication is right for them.
Provided by
The Conversation


This article is republished from The Conversation under a Creative Commons license. Read the original article.The Conversation

Citation:
People on Ozempic may have fewer heart attacks, strokes, addictions—but more nausea, vomiting, stomach pain (2025, January 26)
retrieved 26 January 2025
from https://medicalxpress.com/news/2025-01-people-ozempic-heart-addictions-nausea.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Ozempic
Credit: Pixabay/CC0 Public Domain

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity.

The dramatic effects of these drugs, known as GLP-1s, on weight loss have sparked huge public interest in this new treatment option.

However, the risks and benefits are still being actively studied.

In a new study in Nature Medicine, researchers from the United States reviewed health data from about 2.4 million people who have type 2 diabetes, including around 216,000 people who used a GLP-1 drug, between 2017 and 2023.

The researchers compared a range of health outcomes when GLP-1s were added to a person’s treatment plan, versus managing their diabetes in other ways, often using glucose-lowering medications.

Overall, they found people who used GLP-1s were less likely to experience 42 health conditions or adverse health events—but more likely to face 19 others.

What conditions were less common?

  • Cardiometabolic conditions. GLP-1 use was associated with fewer serious cardiovascular and coagulation disorders. This includes deep vein thrombosis, pulmonary embolism, stroke, cardiac arrest, heart failure and myocardial infarction.
  • Neurological and psychiatric conditions. GLP-1 use was associated with fewer reported substance use disorders or addictions, psychotic disorders and seizures.
  • Infectious conditions. GLP-1 use was associated with fewer bacterial infections and pneumonia.

What conditions were more common?

  • Gastrointestinal conditions. Consistent with prior studies, GLP-1 use was associated with gastrointestinal conditions such as nausea, vomiting, gastritis, diverticulitis and abdominal pain.
  • Other adverse effects. Increased risks were seen for conditions such as low blood pressure, syncope (fainting) and arthritis.

How robust is this study?

The study used a large and reputable dataset from the US Department of Veterans Affairs. It’s an observational study, meaning the researchers tracked health outcomes over time without changing anyone’s treatment plan.

A strength of the study is it captures data from more than 2.4 million people across more than six years. This is much longer than what is typically feasible in an intervention study.

Observational studies like this are also thought to be more reflective of the “real world,” because participants aren’t asked to follow instructions to change their behavior in unnatural or forced ways, as they are in intervention studies.

However, this study cannot say for sure that GLP-1 use was the cause of the change in risk of different health outcomes. Such conclusions can only be confidently made from tightly controlled intervention studies, where researchers actively change or control the treatment or behavior.

The authors note the data used in this study comes from predominantly older, white men, so the findings may not apply to other groups.

Also, the large number of participants means that even very small effects can be detected, but they might not actually make a real difference in overall population health.

Other possible reasons for these links

Beyond the effect of GLP-1 in the body, other factors may explain some of the findings in this study. For example, it’s possible that:

  • People who used GLP-1 could be more informed about treatment options and more motivated to manage their own health
  • People who used GLP-1 may have received it because their health-care team were motivated to offer the latest treatment options, which could lead to better care in other areas that impact the risk of various health outcomes
  • People who used GLP-1 may have been able to do so because they lived in metropolitan centers and could afford the medication, as well as other health-promoting services and products, such as gyms, mental health care, or healthy food delivery services.

Did the authors have any conflicts of interest?

Two of the study’s authors declared they were “uncompensated consultants” for Pfizer, a global pharmaceutical company known for developing a wide range of medicines and vaccines. While Pfizer does not currently make readily available GLP-1s such as Ozempic or Wegovy, they are attempting to develop their own GLP-1s, so may benefit from greater demand for these drugs.

This research was funded by the US Department of Veterans Affairs, a government agency that provides a wide range of services to military veterans.

No other competing interests were reported.

Diabetes vs. weight-loss treatments

Overall, this study shows people with type 2 diabetes using GLP-1 medication generally have more positive health outcomes than negative health outcomes.

However, the study didn’t include people without type 2 diabetes. More research is needed to understand the effects of these medications in people without diabetes who are using them for other reasons, including weight loss.

While the findings highlight the therapeutic benefits of GLP-1 medications, they also raise important questions about how to manage the potential risks for those who choose to use this medication.

The findings of this study can help many people, including:

  • policymakers looking at ways to make GLP-1 medications more widely available for people with various health conditions
  • health professionals who have regular discussions with patients considering GLP-1 use
  • individuals considering whether a GLP-1 medication is right for them.
Provided by
The Conversation


This article is republished from The Conversation under a Creative Commons license. Read the original article.The Conversation

Citation:
People on Ozempic may have fewer heart attacks, strokes, addictions—but more nausea, vomiting, stomach pain (2025, January 26)
retrieved 26 January 2025
from https://medicalxpress.com/news/2025-01-people-ozempic-heart-addictions-nausea.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Worst of SoCal rain storm set to hit Sunday. Monday

Next Post

Kerala govt declares Wayanad Tiger a man-eater after fatal attack on woman, orders killing todayheadline

Related Posts

disability

Experimental drug may benefit some patients with rare form of ALS

May 22, 2025
4
WellTheory raises $5M for AI-enabled autoimmune care platform

WellTheory raises $5M for AI-enabled autoimmune care platform

May 22, 2025
13
Next Post
Kerala govt declares Wayanad Tiger a man-eater after fatal attack on woman, orders killing

Kerala govt declares Wayanad Tiger a man-eater after fatal attack on woman, orders killing todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
North Dakota governor vetoes the housing budget — by mistake

North Dakota governor vetoes the housing budget — by mistake

May 22, 2025

Trump ratchets up battle with Harvard, foreign students: 5 takeaways

May 22, 2025
AI hardware start-ups get fresh boost in Shenzhen with launch of US$1 billion funds

AI hardware start-ups get fresh boost in Shenzhen with launch of US$1 billion funds

May 22, 2025

Trump Confirms Attempted Deportation of Migrants to South Sudan

May 22, 2025

Recent News

North Dakota governor vetoes the housing budget — by mistake

North Dakota governor vetoes the housing budget — by mistake

May 22, 2025
0

Trump ratchets up battle with Harvard, foreign students: 5 takeaways

May 22, 2025
0
AI hardware start-ups get fresh boost in Shenzhen with launch of US$1 billion funds

AI hardware start-ups get fresh boost in Shenzhen with launch of US$1 billion funds

May 22, 2025
3

Trump Confirms Attempted Deportation of Migrants to South Sudan

May 22, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

North Dakota governor vetoes the housing budget — by mistake

North Dakota governor vetoes the housing budget — by mistake

May 22, 2025

Trump ratchets up battle with Harvard, foreign students: 5 takeaways

May 22, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co